scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1014984730 |
P356 | DOI | 10.1186/1471-2407-8-218 |
P932 | PMC publication ID | 2516523 |
P698 | PubMed publication ID | 18671849 |
P5875 | ResearchGate publication ID | 23142010 |
P50 | author | Penella Woll | Q57474508 |
P2093 | author name string | Yong Ming Zhu | |
Danny C W Yu | |||
Nor Saadah M Azahri | |||
P2860 | cites work | Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. | Q45031019 |
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts | Q45101669 | ||
Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. | Q53598685 | ||
Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer | Q53649344 | ||
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. | Q54681218 | ||
NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro | Q72321250 | ||
Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer | Q73259688 | ||
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer | Q74534930 | ||
The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients | Q77357051 | ||
Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer | Q80184030 | ||
Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3 | Q80556469 | ||
Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer | Q28194900 | ||
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus | Q28512617 | ||
Interleukin-8 and human cancer biology | Q34360704 | ||
Expression of cyclooxygenase-2 in human lung carcinoma | Q34755008 | ||
Cyclooxygenase 2: a molecular target for cancer prevention and treatment | Q35057356 | ||
Cyclooxygenase as a target in lung cancer | Q35817554 | ||
Mitogenic effects of interleukin-8/CXCL8 on cancer cells | Q36429600 | ||
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results | Q36512153 | ||
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. | Q36644123 | ||
Overexpression of cyclooxygenase-2 in non-small cell lung cancer | Q38448860 | ||
Interleukin-8/CXCL8 is a growth factor for human lung cancer cells | Q38799309 | ||
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer | Q40282966 | ||
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer | Q40353025 | ||
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels | Q40360880 | ||
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer | Q40583103 | ||
Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase | Q40643170 | ||
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis | Q42435391 | ||
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. | Q43763000 | ||
Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. | Q44378582 | ||
Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. | Q44984368 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung cancer | Q47912 |
endothelium | Q111140 | ||
P304 | page(s) | 218 | |
P577 | publication date | 2008-07-31 | |
P1433 | published in | BMC Cancer | Q326300 |
P1476 | title | Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells | |
P478 | volume | 8 |
Q38288739 | A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. |
Q34290118 | Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer |
Q37727431 | Chitosan oligosaccharides suppress LPS-induced IL-8 expression in human umbilical vein endothelial cells through blockade of p38 and Akt protein kinases |
Q36883777 | Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells |
Q35928999 | Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines |
Q64059711 | Cyclooxygenase-2 Activity Regulates Recruitment of VEGF-Secreting Ly6C Monocytes in Ventilator-Induced Lung Injury |
Q35645052 | Cyclooxygenase-2-expressing macrophages in human pterygium co-express vascular endothelial growth factor |
Q38794384 | Dual Stimuli-Responsive Nanoparticles for Controlled Release of Anticancer and Anti-inflammatory Drugs Combination |
Q26824679 | Effects of intermittent fasting on metabolism in men |
Q39406853 | Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells. |
Q36363166 | Growth and adherence of Staphylococcus aureus were enhanced through the PGE2 produced by the activated COX-2/PGE2 pathway of infected oral epithelial cells |
Q53479155 | Interleukin-8-producing primary cardiac undifferentiated sarcoma in a child with sustained fever. |
Q38053088 | Involvement of β-arrestins in cancer progression |
Q90384113 | Mapping the structure and biological functions within mesenchymal bodies using microfluidics |
Q36903409 | New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis. |
Q33794119 | Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. |
Q35892555 | The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis |
Search more.